Table 1.
Demographic data, underlying medical conditions, clinical manifestations and laboratory findings from three studies of 278 patients with SARS-CoV-2 pneumonia in Wuhan, China [4,5,8]a.
| Huang et al. [5] (n = 41) | Chen et al. [4] (n = 99) | Wang et al. [8] (n = 138) | |
|---|---|---|---|
| Study site | Wuhan local health authority | Wuhan Jinyintan Hospital | Zhongnan Hospital of Wuhan University |
| Age (years) | 49 (41–58) | 55.5 (13.1) | 56 (42–68) |
| ≥65 years | 6 (14.6) | NA | NA |
| Sex | |||
| Male | 30 (73.2) | 67 (67.7) | 75 (54.3) |
| Female | 11 (26.8) | 32 (32.3) | 63 (45.7) |
| Presumed hospital-related infection | NA | NA | 57 (41.3) |
| Healthcare worker | NA | NA | 40 (29.0) |
| Any co-morbidity | 13 (31.7) | 50 (51.5) | 64 (46.4) |
| Co-morbidities | |||
| Cardiovascular disease | 6 (14.6) | 40 (40.4) | 20 (14.5) |
| Hypertension | 6 (14.6) | NA | 43 (31.2) |
| Diabetes | 8 (19.5) | 12 (12.1) | 14 (10.1) |
| Respiratory disease | 1 (2.4) | 1 (1.0) | 4 (2.9) |
| Malignancy | 1 (2.4) | 1 (1.0) | 10 (7.2) |
| Chronic kidney disease | NA | NA | 4 (2.9) |
| Chronic liver disease | 1 (2.4) | NA | 4 (2.9) |
| Symptoms and signs | |||
| Fever | 40 (97.6) | 82 (82.8) | 136 (98.6) |
| Cough | 31 (75.6) | 81 (81.8) | 82 (59.4) |
| Dyspnoea | 22/40 (55.0) | 31 (31.3) | 43 (31.2) |
| Sputum production | 11/38 (28.9) | 37 (26.8) | |
| Myalgia | 18 (43.9) | 11 (11.1) | 48 (34.8) |
| Headache | 3/38 (7.9) | 8 (8.1) | 9 (6.5) |
| Diarrhoea | 1/38 (2.6) | 2 (2.0) | 14 (10.1) |
| Rhinorrhoea | NA | 4 (4.0) | NA |
| Sore throat or pharyngalgia | NA | 5 (5.1) | 24 (17.4) |
| Duration of onset to dyspnoea | 8 (5–13) | NA | 5 (1–10) |
| Duration of onset to hospital admission | 7 (4–8) | NA | 7 (4–8) |
| Duration of onset to ARDS | 9 (8–14) | NA | 8 (6–12) |
| Laboratory findings | |||
| White blood cell count (× 109/L) | 6.2 (4.1–10.5) | 7.5 (3.6) | 4.5 (3.3–6.2) |
| Neutrophil count (× 109/L) | 5.0 (3.3–8.9) | 5.0 (3.3–8.1) | 3.0 (2.0–4.9) |
| Lymphocyte count (× 109/L) | 0.8 (0.6–1.1) | 0.9 (0.5) | 0.8 (0.6–1.1) |
| Platelet count (× 109/L) | 164.5 (131.5–263.0) | 213.5 (79.1) | 163 (123–191) |
| aPTT (s) (range) | 27.0 (24.2–34.1) | 27.3 (10.2) | 31.4 (29.4–33.5) |
| PT (s) (range) | 11.1 (10.1–12.4) | 11.3 (1.9) | 13.0 (12.3–13.7) |
| Creatine kinase (U/L) | 132.5 (62.0–219.0) | 850 (51–184) | 92 (56–130) |
| ALT (U/L) | 32.0 (21.0–50.0) | 39 (22–53) | 24 (16–40) |
| AST (U/L) | 34 (26–48) | 34 (26–48) | 31 (24–51) |
| Total bilirubin (mmol/L) | 11.7 (9.5–13.9) | 15.1 (17.3) | 9.8 (8.4–11.1) |
| Creatinine (μmol/L) | 74.2 (57.5–85.7) | 75.6 (25.0) | 72 (60–87) |
| Lactate dehydrogenase (U/L) | 286 (242–408) | 336 (260–447) | 261 (182–403) |
NA, not available; ARDS, acute respiratory distress syndrome; aPTT, activated partial thromboplastin time; PT, prothrombin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a
Data are n (%), n/N (%), mean (standard deviation) or median (interquartile range).